UA110790C2 - Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні - Google Patents

Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні

Info

Publication number
UA110790C2
UA110790C2 UAA201212456A UAA201212456A UA110790C2 UA 110790 C2 UA110790 C2 UA 110790C2 UA A201212456 A UAA201212456 A UA A201212456A UA A201212456 A UAA201212456 A UA A201212456A UA 110790 C2 UA110790 C2 UA 110790C2
Authority
UA
Ukraine
Prior art keywords
breast cancer
cancer recurrence
endocrine treatment
prediction under
recurrence prediction
Prior art date
Application number
UAA201212456A
Other languages
English (en)
Russian (ru)
Inventor
Марайке ДАРТМАНН
Інке Сабін Федер
Матіас Германн
Гідо Хенніг
Карстен Вебер
Тьорн Крістіан фон
Ральф КРОНЕНВЕТТ
Крістоф Петри
Original Assignee
Сівідон Діагностікс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сівідон Діагностікс Гмбх filed Critical Сівідон Діагностікс Гмбх
Publication of UA110790C2 publication Critical patent/UA110790C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Винахід належить до способу, набору для прогнозування наслідків захворювання при раку молочної залози, причому вказаний спосіб включає: (a) визначення в зразку пухлини від вказаного пацієнта рівнів експресії РНК наступних 8 генів: UBE2C, BIRC5, DHCR7, STC2, AZGP1, RBBP8, IL6ST і MGP; (b) математичне комбінування величин рівня експресії для генів вказаного набору, причому ці величини визначають в зразку пухлини з одержанням комбінованого показника, де вказаний комбінований показник указує на прогноз у вказаного пацієнта.
UAA201212456A 2010-03-31 2011-03-29 Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні UA110790C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10158561 2010-03-31
PCT/EP2011/054855 WO2011120984A1 (en) 2010-03-31 2011-03-29 Method for breast cancer recurrence prediction under endocrine treatment

Publications (1)

Publication Number Publication Date
UA110790C2 true UA110790C2 (uk) 2016-02-25

Family

ID=43857901

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201212456A UA110790C2 (uk) 2010-03-31 2011-03-29 Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні

Country Status (17)

Country Link
US (4) US20130065786A1 (uk)
EP (2) EP2845911B1 (uk)
JP (2) JP5940517B2 (uk)
KR (1) KR101864855B1 (uk)
CN (2) CN102971435B (uk)
BR (2) BR122020016370B1 (uk)
CA (1) CA2793133C (uk)
ES (2) ES2525382T3 (uk)
HK (1) HK1181817A1 (uk)
HU (1) HUE030164T2 (uk)
MX (1) MX2012011167A (uk)
PL (2) PL2553118T3 (uk)
PT (2) PT2845911T (uk)
RU (1) RU2654587C2 (uk)
UA (1) UA110790C2 (uk)
WO (1) WO2011120984A1 (uk)
ZA (1) ZA201207229B (uk)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030198972A1 (en) 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
WO2011120984A1 (en) 2010-03-31 2011-10-06 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
HUE032391T2 (en) 2011-07-28 2017-09-28 Sividon Diagnostics Gmbh A method of predicting a response to chemotherapy in a patient suffering from, or at risk of, recurrent breast cancer
JP6147755B2 (ja) * 2011-11-08 2017-06-14 ジェノミック ヘルス， インコーポレイテッド 乳癌の予後を予測する方法
MX369628B (es) * 2012-05-22 2019-11-14 Nanostring Technologies Inc Genes nano46 y metodos para predecir el resultado del cancer de mama.
WO2013188600A1 (en) * 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
WO2013190081A1 (en) * 2012-06-22 2013-12-27 Proyecto De Biomedicina Cima, S.L. Methods and reagents for the prognosis of cancer
WO2014118333A1 (en) 2013-02-01 2014-08-07 Sividon Diagnostics Gmbh Method for predicting the benefit from inclusion of taxane in a chemotherapy regimen in patients with breast cancer
JP2014236726A (ja) * 2013-05-07 2014-12-18 独立行政法人国立がん研究センター 胃がんの再発を予測する方法
US20160115551A1 (en) * 2013-05-13 2016-04-28 Nanostring Technologies, Inc. Methods to predict risk of recurrence in node-positive early breast cancer
US20160186270A1 (en) * 2013-08-02 2016-06-30 Université Catholique de Louvain Signature of cycling hypoxia and use thereof for the prognosis of cancer
EP3044335B1 (en) * 2013-09-11 2020-09-09 Bio Theranostics, Inc. Predicting breast cancer recurrence
CN105793437B (zh) * 2013-09-23 2020-12-15 芝加哥大学 关于dna损伤制剂用于癌症治疗的方法和组合物
KR101548830B1 (ko) * 2013-12-30 2015-08-31 가천대학교 산학협력단 줄기세포 배양방법을 이용하여 발굴된 유방암 줄기세포 마커를 이용한 유방암 예후 예측용 조성물
RU2711452C2 (ru) * 2014-01-22 2020-01-17 Конинклейке Филипс Н.В. Усовершенствованная стратификация пациентов для оценки пригодности терапии
RU2566732C1 (ru) * 2014-07-08 2015-10-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт онкологии" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИ онкологии" СО РАМН) Способ прогнозирования лимфогенного метастазирования при инвазивной карциноме неспецифического типа молочной железы
CN104263815B (zh) * 2014-08-25 2017-01-25 复旦大学附属肿瘤医院 一组用于激素受体阳性乳腺癌预后的基因及其应用
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
WO2016154600A1 (en) 2015-03-25 2016-09-29 The General Hospital Corporation Digital analysis of circulating tumor cells in blood samples
CA3016677A1 (en) 2016-03-09 2017-09-14 Myriad International Gmbh Method for determining the risk of recurrence of an estrogen receptor-positive and her2-negative primary mammary carcinoma under an endocrine therapy
US11066466B2 (en) * 2016-04-14 2021-07-20 Academia Sinica Inhibition of SCUBE2, a novel VEGFR2 co-receptor, suppresses tumor angiogenesis
JP7131773B2 (ja) * 2016-04-29 2022-09-06 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム ホルモン受容体に関連する転写活性の標的尺度
CN106480201A (zh) * 2016-10-26 2017-03-08 北京鑫诺美迪基因检测技术有限公司 乳腺癌转移评估试剂盒
WO2018081625A2 (en) * 2016-10-27 2018-05-03 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
KR101950717B1 (ko) * 2016-11-23 2019-02-21 주식회사 젠큐릭스 유방암 환자의 화학치료 유용성 예측 방법
KR101896545B1 (ko) * 2016-11-25 2018-09-07 주식회사 젠큐릭스 유방암 환자의 예후 예측 방법
RU2671557C1 (ru) * 2017-07-10 2018-11-02 Александр Григорьевич Тоневицкий Набор реагентов для определения риска возникновения рецидива онкологических заболеваний молочной железы
CA3075265A1 (en) * 2017-09-08 2019-03-14 Myriad Genetics, Inc. Method of using biomarkers and clinical variables for predicting chemotherapy benefit
CN108441559B (zh) * 2018-02-27 2021-01-05 海门善准生物科技有限公司 一种免疫相关基因群作为标志物在制备评估高增殖性乳腺癌远处转移风险的产品中的应用
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
CN108715804A (zh) * 2018-05-14 2018-10-30 浙江大学 一种群智能寻优的肺癌癌细胞检测仪
CN108424969B (zh) * 2018-06-06 2022-07-15 深圳市颐康生物科技有限公司 一种生物标志物、诊断或预估死亡风险的方法
JP2020028278A (ja) * 2018-08-24 2020-02-27 国立大学法人九州大学 被検体に生じるイベントを予測するための判別器の生成方法、及び前記判別器を用いた被検体の層別化方法
US20220042999A1 (en) * 2018-12-06 2022-02-10 Georgia State University Research Foundation, Inc. Quantitative Centrosomal Amplification Score to Predict Local Recurrence of Ductal Carcinoma In Situ
EP3994282A1 (en) * 2019-07-05 2022-05-11 Intellexon GmbH Determining individual hla patterns, use as prognosticators, target genes and therapeutic agents
JP2022547735A (ja) * 2019-09-16 2022-11-15 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 乳房がんの分子特徴付けに基づく処置の方法
KR102325945B1 (ko) * 2020-04-22 2021-11-12 아주대학교산학협력단 두경부암 예후 예측용 바이오마커 조성물
CN112852968A (zh) * 2021-04-08 2021-05-28 杨文琳 基于免疫相关lncRNA构建三阴性乳腺癌风险预测方法
CN114480652A (zh) * 2022-02-21 2022-05-13 深圳市陆为生物技术有限公司 评价乳腺癌患者对于辅助内分泌治疗的响应性的产品

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6686446B2 (en) 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
JP4277452B2 (ja) 2000-02-25 2009-06-10 ソニー株式会社 記録装置、再生装置
EA006512B1 (ru) * 2001-04-27 2005-12-29 Институт молекулярной биологии им. В.А.Энгельгардта РАН Способы анализа последовательностей нуклеиновых кислот с использованием биологического олигонуклеотидного микрочипа и наборы для их осуществления
WO2003001985A2 (en) 2001-06-28 2003-01-09 Dermtech International Method for detection of melanoma
US20040002067A1 (en) 2001-12-21 2004-01-01 Erlander Mark G. Breast cancer progression signatures
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
FR2863275B1 (fr) * 2003-12-09 2007-08-10 Biomerieux Sa Procede pour le diagnostic/pronostic du cancer du sein
MXPA06009545A (es) * 2004-02-20 2007-03-07 Johnson & Johnson Pronosticos del cancer de mama.
US7899623B2 (en) * 2004-09-22 2011-03-01 Tripath Imaging, Inc. Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
WO2006052731A2 (en) 2004-11-05 2006-05-18 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
JP2008536094A (ja) 2005-02-04 2008-09-04 ロゼッタ インファーマティクス エルエルシー 乳癌患者における化学療法反応性を予測する方法
EP1880335A1 (en) * 2005-05-13 2008-01-23 Universite Libre De Bruxelles Gene-based algorithmic cancer prognosis
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
JP2008546387A (ja) 2005-06-13 2008-12-25 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 癌を処置および診断するための組成物および方法
GB0512299D0 (en) 2005-06-16 2005-07-27 Bayer Healthcare Ag Diagnosis prognosis and prediction of recurrence of breast cancer
WO2007030611A2 (en) * 2005-09-09 2007-03-15 The Board Of Regents Of The University Of Texas System A calculated index of genomic expression of estrogen receptor (er) and er related genes
EP2041307A2 (en) * 2006-07-13 2009-04-01 Siemens Healthcare Diagnostics GmbH Prediction of breast cancer response to taxane-based chemotherapy
EP2061885A4 (en) * 2006-09-15 2011-03-09 Univ Mcgill BREAST CANCER INDICATOR DERIVED FROM STROMA
EP2101734B1 (en) 2006-12-01 2013-01-23 The Regents of the University of California Vesicles of self-assembling block copolymers and methods for making and using the same
RU2473555C2 (ru) * 2006-12-19 2013-01-27 ДжинГоу, Инк. Новые способы функционального анализа большого количества экспериментальных данных и групп генов, идентифицированных из указанных данных
CA2690334C (en) 2007-06-08 2017-02-14 Genentech, Inc. Gene expression markers of tumor resistance to her2 inhibitor treatment
EP2036988A1 (en) 2007-09-12 2009-03-18 Siemens Healthcare Diagnostics GmbH A method for predicting the response of a tumor in a patient suffering from or at risk of developing recurrent gynecologic cancer towards a chemotherapeutic agent
WO2009095319A1 (en) 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
US8067178B2 (en) 2008-03-14 2011-11-29 Genomic Health, Inc. Gene expression markers for prediction of patient response to chemotherapy
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
WO2009158143A1 (en) * 2008-05-30 2009-12-30 The University Of North Carolina At Chapel Hill Gene expression profiles to predict breast cancer outcomes
RU2011101382A (ru) 2008-06-16 2012-07-27 Сайвидон Дайагностикс Гмбх (De) Молекулярные маркеры для прогноза развития рака
EP2304631A1 (en) * 2008-06-16 2011-04-06 Sividon Diagnostics GmbH Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer
EP2163649A1 (en) * 2008-09-11 2010-03-17 Fédération Nationale des Centres de Lutte Contre le Cancer Molecular classifier for evaluating the risk of metastasic relapse in breast cancer
KR101161789B1 (ko) 2008-12-10 2012-07-03 한국생명공학연구원 간암에 대한 신규 바이오마커 및 그의 용도
WO2010076322A1 (en) * 2008-12-30 2010-07-08 Siemens Healthcare Diagnostics Inc. Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer
EP2419532A1 (en) 2009-04-17 2012-02-22 Université Libre de Bruxelles Methods and tools for predicting the efficiency of anthracyclines in cancer
EP2432872B1 (en) 2009-05-22 2015-09-30 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Akt phosphorylation at ser473 as an indicator for taxane-based chemotherapy
EP2553119B1 (en) 2010-03-30 2016-03-30 Ralph Wirtz Algorithm for prediction of benefit from addition of taxane to standard chemotherapy in patients with breast cancer
WO2011120984A1 (en) 2010-03-31 2011-10-06 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
US20130042333A1 (en) 2011-05-06 2013-02-14 Jean-Gabriel JUDDE Markers for cancer prognosis and therapy and methods of use
HUE032391T2 (en) 2011-07-28 2017-09-28 Sividon Diagnostics Gmbh A method of predicting a response to chemotherapy in a patient suffering from, or at risk of, recurrent breast cancer
WO2013078537A1 (en) 2011-11-28 2013-06-06 National Research Council Of Canada Paclitaxel response markers for cancer
WO2013188600A1 (en) 2012-06-12 2013-12-19 Washington University Copy number aberration driven endocrine response gene signature
AU2015217698A1 (en) 2014-02-12 2016-06-30 Sividon Diagnostics Gmbh Method for predicting the response and survival from chemotherapy in patients with breast cancer
CN106480201A (zh) 2016-10-26 2017-03-08 北京鑫诺美迪基因检测技术有限公司 乳腺癌转移评估试剂盒

Also Published As

Publication number Publication date
HUE030164T2 (en) 2017-05-29
RU2654587C2 (ru) 2018-05-21
JP2016189781A (ja) 2016-11-10
CN102971435B (zh) 2016-05-11
US20170067118A1 (en) 2017-03-09
ES2525382T3 (es) 2014-12-23
ZA201207229B (en) 2013-06-26
CN105821125A (zh) 2016-08-03
EP2845911A1 (en) 2015-03-11
EP2845911B1 (en) 2016-05-18
PT2845911T (pt) 2016-08-25
ES2587591T3 (es) 2016-10-25
PL2845911T3 (pl) 2017-01-31
AU2011234573B2 (en) 2015-10-01
US10851427B2 (en) 2020-12-01
PL2553118T3 (pl) 2015-03-31
EP2553118A1 (en) 2013-02-06
US20200224281A1 (en) 2020-07-16
CA2793133C (en) 2019-08-20
US10577661B2 (en) 2020-03-03
CA2793133A1 (en) 2011-10-06
KR20130010048A (ko) 2013-01-24
BR112012024718A2 (pt) 2017-01-10
JP2013523105A (ja) 2013-06-17
EP2553118B1 (en) 2014-10-15
US20130065786A1 (en) 2013-03-14
KR101864855B1 (ko) 2018-07-13
HK1181817A1 (en) 2013-11-15
JP5940517B2 (ja) 2016-06-29
MX2012011167A (es) 2013-02-07
US20210123107A1 (en) 2021-04-29
CN102971435A (zh) 2013-03-13
BR122020016370B1 (pt) 2021-05-11
AU2011234573A1 (en) 2012-09-20
PT2553118E (pt) 2014-12-17
WO2011120984A1 (en) 2011-10-06
RU2012146343A (ru) 2014-05-10
US11913078B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
UA110790C2 (uk) Спосіб передбачування рецидиву раку молочної залози при ендокринному лікуванні
Tsz-fung et al. Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis
Li et al. Expression of serum miR-221 in human hepatocellular carcinoma and its prognostic significance
Chen et al. Identification of microRNA‐214 as a negative regulator of colorectal cancer liver metastasis by way of regulation of fibroblast growth factor receptor 1 expression
Hoppe et al. Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptor-positive breast cancer following tamoxifen treatment
Chu et al. Identification of novel piRNAs in bladder cancer
Bellavia et al. Deregulated miRNAs in osteoporosis: effects in bone metastasis
Feber et al. MicroRNA prognostic signature for nodal metastases and survival in esophageal adenocarcinoma
Shi et al. Long non-coding RNA Loc554202 regulates proliferation and migration in breast cancer cells
Yuan et al. Comprehensive analysis of lncRNA-associated ceRNA network in colorectal cancer
Wu et al. Potentially predictive microRNAs of gastric cancer with metastasis to lymph node
IN2012DN04944A (uk)
JP2014532428A5 (uk)
NZ705645A (en) Method to use gene expression to determine likelihood of clinical outcome of renal cancer
JP2018504915A (ja) 尿中の前立腺癌の早期発見のためのｍｉｃｒｏＲＮＡに基づく方法
Maltseva et al. miRNome of inflammatory breast cancer
NZ599194A (en) Methods to predict clinical outcome of cancer
Yu et al. Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer
WO2009133915A1 (ja) 癌マーカー、それを用いた癌の評価方法および評価試薬
WO2014057357A3 (en) Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-maf
Sun et al. Screening of differently expressed miRNA and mRNA in prostate cancer by integrated analysis of transcription data
Wang et al. Expression of lncRNA HULC in cervical cancer and its correlation with tumor progression and patient survival.
WO2011153545A3 (en) Gene expression signature as a predictor of chemotherapeutic response in breast cancer
Liu et al. Identification of aberrantly expressed miRNAs in gastric cancer
Chen et al. Circulating miR-148b-3p and miR-409-3p as biomarkers for heart failure in patients with mitral regurgitation